Symptoms of COVID-19

Last updated

Symptoms of COVID-19 Symptoms of coronavirus disease 2019 4.0.svg
Symptoms of COVID-19

The symptoms of COVID-19 are variable depending on the type of variant contracted, ranging from mild symptoms to a potentially fatal illness. [1] [2] Common symptoms include coughing, fever, loss of smell (anosmia) and taste (ageusia), with less common ones including headaches, nasal congestion and runny nose, muscle pain, sore throat, diarrhea, eye irritation, [3] and toes swelling or turning purple, [4] and in moderate to severe cases, breathing difficulties. [5] People with the COVID-19 infection may have different symptoms, and their symptoms may change over time.

Contents

Three common clusters of symptoms have been identified: a respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; and a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea. [5] In people without prior ear, nose, or throat disorders, loss of taste combined with loss of smell is associated with COVID-19 and is reported in as many as 88% of symptomatic cases. [6] [7] [8]

Published data on the neuropathological changes related with COVID-19 have been limited and contentious, with neuropathological descriptions ranging from moderate to severe hemorrhagic and hypoxia phenotypes, thrombotic consequences, changes in acute disseminated encephalomyelitis (ADEM-type), encephalitis and meningitis. Many COVID-19 patients with co-morbidities have hypoxia and have been in intensive care for varying lengths of time, confounding interpretation of the data. [9]

Of people who show symptoms, 81% develop only mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging) that require hospitalization, and 5% of patients develop critical symptoms (respiratory failure, septic shock, or multiorgan dysfunction) requiring ICU admission. [10] [ needs update ]

Proportion of asymptomatic SARS-CoV-2 infection by age. About 44% of those infected with SARS-CoV-2 remained asymptomatic throughout the infection. Asymptomatic COVID by age.jpg
Proportion of asymptomatic SARS-CoV-2 infection by age. About 44% of those infected with SARS-CoV-2 remained asymptomatic throughout the infection.

At least a third of the people who are infected with the virus do not develop noticeable symptoms at any point in time. [11] [12] [13] These asymptomatic carriers tend not to get tested and can still spread the disease. [13] [14] [15] [16] Other infected people will develop symptoms later (called "pre-symptomatic") or have very mild symptoms and can also spread the virus. [16]

As is common with infections, there is a delay, or incubation period, between the moment a person first becomes infected and the appearance of the first symptoms. The median delay for COVID-19 is four to five days [17] possibly being infectious on 1–4 of those days. [18] Most symptomatic people experience symptoms within two to seven days after exposure, and almost all will experience at least one symptom within 12 days. [17] [19]

Most people recover from the acute phase of the disease. However, some people continue to experience a range of effects, such as fatigue, for prolonged periods after an initial COVID-19 infection. [20] This is the result of a condition called long COVID, which can be described as a range of persistent symptoms that continue for months or years. [20] Long-term damage to organs has been observed after the onset of COVID-19. Multi-year studies are underway to further investigate the protracted effects of long COVID. [20] Reducing the risk of long COVID includes staying up to date on the most recent COVID-19 vaccine, practicing good hygiene, maintaining clean indoor air, and physical distancing from people infected with a respiratory virus. [20]

The Omicron variant became dominant in the U.S. in December 2021. Symptoms with the Omicron variant are less severe than they are with other variants. [21]

Overview

Symptoms of COVID-19 Symptoms of COVID-19 (English).pdf
Symptoms of COVID-19

Some less common symptoms of COVID-19 can be relatively non-specific; however the most common symptoms are fever, dry cough, and loss of taste and smell. [1] [22] Among those who develop symptoms, approximately one in five may become more seriously ill and have difficulty in breathing. Emergency symptoms include difficulty in breathing, persistent chest pain or pressure, sudden confusion, loss of mobility and speech, and bluish face or lips; immediate medical attention is advised if these symptoms are present. [1] Further development of the disease can lead to complications including pneumonia, acute respiratory distress syndrome, sepsis, septic shock, and kidney failure.

Some symptoms usually appear sooner than others, with deterioration usually developing in the second week. [23] In August 2020, scientists at the University of Southern California reported the "likely" order of initial symptoms of the COVID-19 disease as a fever followed by a cough and muscle pain, and that nausea and vomiting usually appear before diarrhea. [24] [ non-primary source needed ] This contrasts with the most common path for influenza where it is common to develop a cough first and fever later. [24] Impaired immunity in part drive disease progression after SARS-CoV-2 infection. [25] While health agency guidelines tend to recommend isolating for 14 days while watching for symptoms to develop, [26] there is limited evidence that symptoms may develop for some patients more than 14 days after initial exposure. [27]

Symptom profile of variants

The frequency of symptoms predominating for people with different variants may differ from what was observed in the earlier phases of the pandemic.

Delta

People infected with the Delta variant may mistake the symptoms for a bad cold and not realize they need to isolate. Common symptoms reported as of June 2021 have been headaches, sore throat, runny nose, and fever. [28] [ medical citation needed ] [29]

Omicron

British epidemiologist Tim Spector said in mid-December 2021 that the majority of symptoms of the Omicron variant were the same as a common cold, including headaches, sore throat, runny nose, fatigue and sneezing, so that people with cold symptoms should take a test. "Things like fever, cough and loss of smell are now in the minority of symptoms we are seeing. Most people don't have classic symptoms." People with cold symptoms in London (where Covid was spreading rapidly) are "far more likely" to have Covid than a cold. [30]

A unique reported symptom of the Omicron variant is night sweats, [31] particularly with the BA.5 subvariant. [32] Also, loss of taste and smell seem to be uncommon compared to other strains. [33] [34]

Systemic

Typical systemic symptoms include fatigue, and muscle and joint pains. Some people have a sore throat. [1] [2] [22]

Fever

Fever is one of the most common symptoms in COVID-19 patients. However, the absence of the symptom itself at an initial screening does not rule out COVID-19. Fever in the first week of a COVID-19 infection is part of the body's natural immune response; however in severe cases, if the infections develop into a cytokine storm the fever is counterproductive. As of September 2020, little research had focused on relating fever intensity to outcomes. [35]

A June 2020 systematic review reported a 75–81% prevalence of fever. [2] As of July 2020, the European Centre for Disease Prevention and Control (ECDC) reported a prevalence rate of ~45% for fever. [5]

Pain

A June 2020 systematic review reported a 27–35% prevalence of fatigue, 14–19% for muscle pain, 10–14% for sore throat. [2] As of July 2020, the ECDC reported a prevalence rate of ~63% for muscle weakness (asthenia), ~63% for muscle pain (myalgia), and ~53% for sore throat. [5]

Respiratory

Cough is another typical symptom of COVID-19, which could be either dry or a productive cough. [2]

Some symptoms, such as difficulty breathing, are more common in patients who need hospital care. [1] Shortness of breath tends to develop later in the illness. Persistent anosmia or hyposmia or ageusia or dysgeusia has been documented in 20% of cases for longer than 30 days. [6] [7]

Respiratory complications may include pneumonia and acute respiratory distress syndrome (ARDS). [36] [37] [38] [39]

As of July 2020, the ECDC reported a prevalence rate of ~68% for nasal obstruction, ~63% for cough, ~60% for rhinorrhoea or runny nose. [5] A June 2020 systematic review reported a 54–61% prevalence of dry cough and 22–28% for productive cough. [2]

Presence of Sars-CoV-2 virus RNA in the lung. Covid-19 lung showed virus replication in the desquamated lung epithelial cells. Ubiquitin C positive control (Left), COVSPIKE (middle), and dap B negative control (right). Presence of Sars-CoV-2 virus RNA in the lung.jpg
Presence of Sars-CoV-2 virus RNA in the lung. Covid-19 lung showed virus replication in the desquamated lung epithelial cells. Ubiquitin C positive control (Left), COVSPIKE (middle), and dap B negative control (right).

Cardiovascular

Coagulopathy is established to be associated with COVID-19 in those patients in critical state. [41] Thromboembolic events, such as blood clots show with high risk in COVID-19 patients in some studies. [42]

Other cardiovascular complications may include heart failure, arrhythmias, and heart inflammation. [43] [44] [45] They are common traits in severe COVID-19 patients due to the relation with the respiratory system. [46]

Hypertension seems to be the most prevalent risk factor for myocardial injury in COVID-19 disease. It was reported in 58% of individuals with cardiac injury in a recent meta-analysis. [47]

Several cases of acute myocarditis associated with COVID-19 have been described around the globe and are diagnosed in multiple ways. Taking into consideration serology, leukocytosis with neutrophilia and lymphopenia was found in many patients. Cardiac biomarkers troponin and N-terminal (NT)-prohormone BNP (NT-proBNP) were seen elevated. Similarly, the level of inflammation-related markers such as C-reactive protein (CRP), D-dimer, IL-6, procalcitonin was significantly increased, indicating an inflammatory process in the body. Electrocardiogram findings were variable and ranged from sinus tachycardia, ST-segment elevation, T-wave inversion and ST-depression. [48] In one case, viral particles were seen in the interstitial cell, and another case reported SARS-CoV-2 RT–PCR positivity in the cardiac tissue suggestive of direct viral injury to the myocardium. [49] [50] Endomyocardial biopsy [EMB] remains the gold standard invasive technique in diagnosing myocarditis; however, due to the increased risk of infection, it is not done in COVID-19 patients.[ citation needed ]

The binding of the SARS-CoV-2 virus through ACE2 receptors present in heart tissue may be responsible for direct viral injury leading to myocarditis. [48] In a study done during the SARS outbreak, SARS virus RNA was ascertained in the autopsy of heart specimens in 35% of the patients who died due to SARS. [51] It was also observed that an already diseased heart has increased expression of ACE2 receptor contrasted to healthy individuals. [52] Hyperactive immune responses in COVID-19 Patients may lead to the initiation of the cytokine storm. This excess release of cytokines may lead to myocardial injury. [48]

Neurological

Patients with COVID-19 can present with neurological symptoms that can be broadly divided into central nervous system involvement, such as headache, dizziness, altered mental state, and disorientation, and peripheral nervous system involvement, such as anosmia and dysgeusia. [53] As was noted, COVID-19 has also been linked to various neurological symptoms at the diagnosis or throughout the disease, with over 90% of individuals with COVID-19 having reported at least one subjective neurological symptom. [54] Some patients experience cognitive dysfunction called "COVID fog", or "COVID brain fog", involving memory loss, inattention, poor concentration or disorientation. [55] [56] Other neurologic manifestations include seizures, strokes, encephalitis, and Guillain–Barré syndrome (which includes loss of motor functions). [57] [58]

As of July 2020, the ECDC reported a prevalence rate of ~70% for headache. [5] A June 2020 systematic review reported a 10–16% prevalence of headache. [2] However, headache could be mistaken for having a random relationship with COVID-19; there is unambiguous evidence that COVID-19 patients who had never had a recurrent headache suddenly get a severe headache daily because of SARS-CoV-2 infection. [54]

Loss of smell

In about 60% of COVID-19 patients, chemosensory deficit are reported, including losing their sense of smell, either partially or fully. [59] [60] [61]

This symptom, if it is present at all, often appears early in the illness. [59] Its onset is often reported to be sudden. Smell usually returns to normal within a month. However, for some patients it improves very slowly and is associated with odors being perceived as unpleasant or different from they originally did (parosmia), and for some people smell does not return for at least many months. [60] It is an unusual symptom for other respiratory diseases, so it is used for symptom-based screening. [59] [60]

Loss of smell has several consequences. Loss of smell increases foodborne illness due to inability to detect spoiled food, and may increase fire hazards due to inability to detect smoke. It has also been linked to depression. If smell does not return, smell training is a potential option. [60]

It is sometimes the only symptom to be reported, implying that it has a neurological basis separate from nasal congestion. As of January 2021, it is believed that these symptoms are caused by infection of sustentacular cells that support and provide nutrients to sensory neurons in the nose, rather than infection of the neurons themselves. Sustentacular cells have many Angiotensin-converting enzyme 2 (ACE2) receptors on their surfaces, while olfactory sensory neurons do not. Loss of smell may also be the result of inflammation in the olfactory bulb. [60]

A June 2020 systematic review found a 29–54% prevalence of olfactory dysfunction for people with COVID-19, [59] while an August 2020 study using a smell-identification test reported that 96% of people with COVID-19 had some olfactory dysfunction, and 18% had total smell loss. [60] Another June 2020 systematic review reported a 4–55% prevalence of hyposmia. [2] As of July 2020, the ECDC reported a prevalence rate of ~70% for loss of smell. [5]

A disturbance in smell or taste is more commonly found in younger people, and perhaps because of this, it is correlated with a lower risk of medical complications. [59]

Loss of taste and chemesthesis

In some people, COVID-19 causes people to temporarily experience changes in how food tastes (dysgeusia or ageusia). [59] [60] Changes to chemesthesis, which includes chemically triggered sensations such as spiciness, are also reported. As of January 2021, the mechanism for taste and chemesthesis symptoms were not well understood. [60]

A June 2020 systematic review found a 24–54% prevalence of gustatory dysfunction for people with COVID-19. [59] Another June 2020 systematic review reported a 1–8% prevalence of hypogeusia. [2] As of July 2020, the ECDC reported a prevalence rate of ~54% for gustatory dysfunction. [5]

Other neurological and psychiatric symptoms

Other neurological symptoms appear to be rare, but may affect half of patients who are hospitalized with severe COVID-19. Some reported symptoms include delirium, stroke, brain hemorrhage, memory loss, psychosis, peripheral nerve damage, anxiety, and post-traumatic stress disorder. [62] Neurological symptoms in many cases are correlated with damage to the brain's blood supply or encephalitis, which can progress in some cases to acute disseminated encephalomyelitis. Strokes have been reported in younger people without conventional risk factors. [63]

As of September 2020, it was unclear whether these symptoms were due to direct infection of brain cells, or of overstimulation of the immune system. [63]

A June 2020 systematic review reported a 6–16% prevalence of vertigo or dizziness, 7–15% for confusion, and 0–2% for ataxia. [2]

Blood clots and bleeding

Patients are at increased risk of a range of different blood clots, some potentially fatal, for months following COVID infection. The Guardian wrote, "Overall, they [a Swedish medical team] identified a 33-fold increase in the risk of pulmonary embolism, a fivefold increase in the risk of DVT (deep vein thrombosis) and an almost twofold increase in the risk of bleeding in the 30 days after infection. People remained at increased risk of pulmonary embolism for six months after becoming infected, and for two and three months for bleeding and DVT. Although the risks were highest in patients with more severe illness, even those with mild Covid had a threefold increased risk of DVT and a sevenfold increased risk of pulmonary embolism. No increased risk of bleeding was found in those who experienced mild infections." Anne-Marie Fors Connolly at Umeå University said, "If you suddenly find yourself short of breath, and it doesn't pass, [and] you've been infected with the coronavirus, then it might be an idea to seek help, because we find this increased risk for up to six months." [64]

Other

Pruritic rash COVID.jpg
Itchy rash in COVID. 61-year-old woman. Small erythematous spots are observed.
Alteracion dermatologica en los dedos de los pies provocada por coronavirus.jpg
Chilblain-like lesions in a patient with coronavirus infection.

Other symptoms are less common among people with COVID-19. Some people experience gastrointestinal symptoms such as loss of appetite, diarrhea, nausea or vomiting. [1] [65] A June 2020 systematic review reported a 8–12% prevalence of diarrhea, and 3–10% for nausea. [2]

Less common symptoms include chills, coughing out blood, diarrhea, and rash. [22] [66] The so-called "COVID toes" are pink to violaceous papules arising on the hands and feet. These chilblain-like lesions often occur only in younger patients and do not appear until late in the disease or during convalescence. [67] Certain genetic polymorphisms (in the TREX1 gene) have been linked to susceptibility towards developing COVID-toe. [68] A June 2020 systematic review reported a 0–1% prevalence of rash in COVID-19 patients. [2]

Approximately 20–30% of people who present with COVID-19 have elevated liver enzymes, reflecting liver injury. [69] [70]

Complications include multi-organ failure, septic shock, and death. [36] [37] [38] [39] [ excessive citations ]

Stages of COVID-19 infection

There are three stages, according to the way COVID-19 infection can be tackled by pharmacological agents, in which the disease can be classified. [71] Stage I is the early infection phase during which the domination of upper respiratory tract symptoms is present. Stage II is the pulmonary phase in which the patient develops pneumonia with all its associated symptoms; this stage is split with Stage IIa which is without hypoxia and Stage IIb which includes hypoxia. Stage III is the hyperinflammation phase, the most severe phase, in which the patient develops acute respiratory distress syndrome (ARDS), sepsis and multi-organ failure. [71]

A similar stereotyped course was postulated to be: the first phase of an incubation period, a second phase corresponding to the viral phase, a third phase corresponding to the state of inflammatory pneumonia, a fourth phase corresponding to the brutal clinical aggravation reflected by acute respiratory distress syndrome (ARDS), and finally, in survivors, a fifth phase potentially including lung fibrosis, and persisting in the form of "post-covid" symptoms. [72]

Longer-term effects

Multisystem inflammatory syndrome in children

Following the infection, children may develop multisystem inflammatory syndrome, also called paediatric multisystem inflammatory syndrome. This has symptoms similar to Kawasaki disease, which can possibly be fatal. [73] [74] [75]

Long COVID

This section is an excerpt from COVID-19 § Long-term effects.[ edit ]

Around 10% to 30% of non-hospitalised people with COVID-19 go on to develop long COVID. For those that do need hospitalisation, the incidence of long-term effects is over 50%. [76] Long COVID is an often severe multisystem disease with a large set of symptoms. There are likely various, possibly coinciding, causes. [76] Organ damage from the acute infection can explain a part of the symptoms, but long COVID is also observed in people where organ damage seems to be absent. [77]

By a variety of mechanisms, the lungs are the organs most affected in COVID‑19. [78] In people requiring hospital admission, up to 98% of CT scans performed show lung abnormalities after 28 days of illness even if they had clinically improved. [79] People with advanced age, severe disease, prolonged ICU stays, or who smoke are more likely to have long-lasting effects, including pulmonary fibrosis. [80] Overall, approximately one-third of those investigated after four weeks will have findings of pulmonary fibrosis or reduced lung function as measured by DLCO, even in asymptomatic people, but with the suggestion of continuing improvement with the passing of more time. [78] After severe disease, lung function can take anywhere from three months to a year or more to return to previous levels. [81]

The risks of cognitive deficit, dementia, psychotic disorders, and epilepsy or seizures persists at an increased level two years after infection. [82]

Post-COVID Condition

Longer-term effects of COVID-19 have become a prevalent aspect of the disease itself. These symptoms can be referred to as many different names including post-COVID-19 syndrome, long COVID, and long haulers syndrome. An overall definition of post-COVID conditions (PCC) can be described as a range of symptoms that can last for weeks or months. [83] Long COVID can be present in anyone who has contracted COVID-19 at some point; typically, it is more commonly found in those who had severe illness due to the virus. [83] [84]

Symptoms

Long COVID can attack a multitude of organs such as the lungs, heart, blood vessels, kidneys, gut, and brain. [85] Some common symptoms that occur as a result are fatigue, cough, shortness of breath, chest pains, brain fog, gastrointestinal issues, insomnia, anxiety/depression, and delirium. [86] A difference between acute COVID-19 and PCC is the effect that it has on a person's mind. People are found to be dealing with brain fog and impaired memory, and diminished learning ability which has a large impact on their everyday lives. [84] [87] A study that took a deeper look into these specific symptoms took 50 SARS-CoV-2 laboratory-positive patients and 50 SARS-CoV-2 laboratory-negative patients to analyze the variety of neurologic symptoms present during long COVID. The most frequent symptoms included brain fog, headache, numbness, dysgeusia (loss of taste), anosmia (loss of smell), and myalgias (muscle pains) with an overall decrease in quality of life. [84]

Related Research Articles

<span class="mw-page-title-main">Anosmia</span> Inability to smell

Anosmia, also known as smell blindness, is the loss of the ability to detect one or more smells. Anosmia may be temporary or permanent. It differs from hyposmia, which is a decreased sensitivity to some or all smells.

<span class="mw-page-title-main">Common cold</span> Common viral infection of the upper respiratory tract

The common cold or the cold is a viral infectious disease of the upper respiratory tract that primarily affects the respiratory mucosa of the nose, throat, sinuses, and larynx. Signs and symptoms may appear in as little as two days after exposure to the virus. These may include coughing, sore throat, runny nose, sneezing, headache, and fever. People usually recover in seven to ten days, but some symptoms may last up to three weeks. Occasionally, those with other health problems may develop pneumonia.

<span class="mw-page-title-main">SARS</span> Disease caused by severe acute respiratory syndrome coronavirus

Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by the virus SARS-CoV-1, the first identified strain of the SARS-related coronavirus. The first known cases occurred in November 2002, and the syndrome caused the 2002–2004 SARS outbreak. In the 2010s, Chinese scientists traced the virus through the intermediary of Asian palm civets to cave-dwelling horseshoe bats in Xiyang Yi Ethnic Township, Yunnan.

<span class="mw-page-title-main">Myocarditis</span> Inflammation of the heart muscle

Myocarditis is defined as inflammation of the myocardium. Myocarditis can progress to inflammatory cardiomyopathy when there are associated ventricular remodeling and cardiac dysfunction due to chronic inflammation. Symptoms can include shortness of breath, chest pain, decreased ability to exercise, and an irregular heartbeat. The duration of problems can vary from hours to months. Complications may include heart failure due to dilated cardiomyopathy or cardiac arrest.

<span class="mw-page-title-main">Upper respiratory tract infection</span> Infection of the nose, sinuses, pharynx, larynx or trachea

An upper respiratory tract infection (URTI) is an illness caused by an acute infection, which involves the upper respiratory tract, including the nose, sinuses, pharynx, larynx or trachea. This commonly includes nasal obstruction, sore throat, tonsillitis, pharyngitis, laryngitis, sinusitis, otitis media, and the common cold. Most infections are viral in nature, and in other instances, the cause is bacterial. URTIs can also be fungal or helminthic in origin, but these are less common.

<span class="mw-page-title-main">Lower respiratory tract infection</span> Medical term

Lower respiratory tract infection (LRTI) is a term often used as a synonym for pneumonia but can also be applied to other types of infection including lung abscess and acute bronchitis. Symptoms include shortness of breath, weakness, fever, coughing and fatigue. A routine chest X-ray is not always necessary for people who have symptoms of a lower respiratory tract infection.

Ageusia is the loss of taste functions of the tongue, particularly the inability to detect sweetness, sourness, bitterness, saltiness, and umami. It is sometimes confused with anosmia – a loss of the sense of smell. True ageusia is relatively rare compared to hypogeusia – a partial loss of taste – and dysgeusia – a distortion or alteration of taste.

Hypogeusia can be defined as the reduced ability to taste things. Due to a lack of stratification, the prevalence of hypogeusia, as well as hyposmia, may not be accurately known. Additionally, reviews do not always make distinctions between ageusia and hypogeusia, often classifying them as the same in certain circumstances and studies. The severity of the loss of taste from hypogeusia is not clearly outlined in current research due to these reasons.

<span class="mw-page-title-main">Post-viral cerebellar ataxia</span> Medical condition

Post-viral cerebellar ataxia also known as acute cerebellitis and acute cerebellar ataxia (ACA) is a disease characterized by the sudden onset of ataxia following a viral infection. The disease affects the function or structure of the cerebellum region in the brain.

<span class="mw-page-title-main">MERS</span> Viral respiratory infection

Middle East respiratory syndrome (MERS) is a viral respiratory infection caused by Middle East respiratory syndrome–related coronavirus (MERS-CoV). Symptoms may range from none, to mild, to severe depending on age and risk level. Typical symptoms include fever, cough, diarrhea, and shortness of breath. The disease is typically more severe in those with other health problems.

<span class="mw-page-title-main">COVID-19 pandemic</span> Pandemic caused by SARS-CoV-2

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began with an outbreak of COVID-19 in Wuhan, China, in December 2019. It spread to other areas of Asia, and then worldwide in early 2020. The World Health Organization (WHO) declared the outbreak a public health emergency of international concern (PHEIC) on 30 January 2020, and assessed the outbreak as having become a pandemic on 11 March.

<span class="mw-page-title-main">COVID-19</span> Contagious disease caused by SARS-CoV-2

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019. Most scientists believe the SARS-CoV-2 virus entered into human populations through natural zoonosis, similar to the SARS-CoV-1 and MERS-CoV outbreaks, and consistent with other pandemics in human history. Social and environmental factors including climate change, natural ecosystem destruction and wildlife trade increased the likelihood of such zoonotic spillover. The disease quickly spread worldwide, resulting in the COVID-19 pandemic.

<span class="mw-page-title-main">COVID-19 testing</span> Diagnostic testing for SARS-CoV-2 virus infection

COVID-19 testing involves analyzing samples to assess the current or past presence of SARS-CoV-2, the virus that cases COVID-19 and is responsible for the COVID-19 pandemic. The two main types of tests detect either the presence of the virus or antibodies produced in response to infection. Molecular tests for viral presence through its molecular components are used to diagnose individual cases and to allow public health authorities to trace and contain outbreaks. Antibody tests instead show whether someone once had the disease. They are less useful for diagnosing current infections because antibodies may not develop for weeks after infection. It is used to assess disease prevalence, which aids the estimation of the infection fatality rate.

<span class="mw-page-title-main">COVID-19 drug repurposing research</span> Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

<span class="mw-page-title-main">Multisystem inflammatory syndrome in children</span> Disease of children; pediatric comorbidity from COVID-19

Multisystem inflammatory syndrome in children (MIS-C), or paediatric inflammatory multisystem syndrome, or systemic inflammatory syndrome in COVID-19 (SISCoV), is a rare systemic illness involving persistent fever and extreme inflammation following exposure to SARS-CoV-2, the virus responsible for COVID-19. Studies suggest that MIS-C occurred in 31.6 out of 100,000 people under 21 who were infected with COVID-19. MIS-C has also been monitored as a potential, rare pediatric adverse event following COVID-19 vaccination. Research suggests that COVID-19 vaccination lowers the risk of MIS-C, and in cases where symptoms develop after vaccine, is likely extremely rare or related to factors like recent exposure to COVID-19. It can rapidly lead to medical emergencies such as insufficient blood flow around the body. Failure of one or more organs can occur. A warning sign is unexplained persistent fever with severe symptoms following exposure to COVID-19. Prompt referral to paediatric specialists is essential, and families need to seek urgent medical assistance. Most affected children will need intensive care.

<span class="mw-page-title-main">Impact of the COVID-19 pandemic on other health issues</span> Health consequences of outbreak beyond the COVID-19 disease itself

The COVID-19 pandemic has had many impacts on global health beyond those caused by the COVID-19 disease itself. It has led to a reduction in hospital visits for other reasons. There have been 38 per cent fewer hospital visits for heart attack symptoms in the United States and 40 per cent fewer in Spain. The head of cardiology at the University of Arizona said, "My worry is some of these people are dying at home because they're too scared to go to the hospital." There is also concern that people with strokes and appendicitis are not seeking timely treatment. Shortages of medical supplies have impacted people with various conditions.

The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the estimated millions of immunocompromised persons who are unlikely to respond robustly to vaccination, treatment remains important. Some people may experience persistent symptoms or disability after recovery from the infection, known as long COVID, but there is still limited information on the best management and rehabilitation for this condition.

<span class="mw-page-title-main">Transmission of COVID-19</span> Mechanisms that spread coronavirus disease 2019

The transmission of COVID-19 is the passing of coronavirus disease 2019 from person to person. COVID-19 is mainly transmitted when people breathe in air contaminated by droplets/aerosols and small airborne particles containing the virus. Infected people exhale those particles as they breathe, talk, cough, sneeze, or sing. Transmission is more likely the closer people are. However, infection can occur over longer distances, particularly indoors.

Long COVID or long-haul COVID is a group of health problems persisting or developing after an initial period of COVID-19 infection. Symptoms can last weeks, months or years and are often debilitating. The World Health Organization defines long COVID as starting three months after the initial COVID-19 infection, but other agencies define it as starting at four weeks after the initial infection.

<span class="mw-page-title-main">Impact of COVID-19 on neurological, psychological and other mental health outcomes</span>

There is increasing evidence suggesting that COVID-19 causes both acute and chronic neurologicalor psychological symptoms. Caregivers of COVID-19 patients also show a higher than average prevalence of mental health concerns. These symptoms result from multiple different factors.

References

  1. 1 2 3 4 5 6 "Symptoms of Coronavirus". U.S. Centers for Disease Control and Prevention (CDC). 22 February 2021. Archived from the original on 4 March 2021. Retrieved 4 March 2021.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. (23 June 2020). "The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries". PLOS ONE. 15 (6): e0234765. Bibcode:2020PLoSO..1534765G. doi: 10.1371/journal.pone.0234765 . PMC   7310678 . PMID   32574165. S2CID   220046286.
  3. ↑ Pardhan S, Vaughan M, Zhang J, Smith L, Chichger H (1 November 2020). "Sore eyes as the most significant ocular symptom experienced by people with COVID-19: a comparison between pre-COVID-19 and during COVID-19 states". BMJ Open Ophthalmology. 5 (1): e000632. doi:10.1136/bmjophth-2020-000632. PMC   7705420 . PMID   34192153.
  4. ↑ "COVID toes, rashes: How the coronavirus can affect your skin". www.aad.org. Retrieved 20 March 2022.
  5. 1 2 3 4 5 6 7 8 "Clinical characteristics of COVID-19". European Centre for Disease Prevention and Control. 10 June 2020. Retrieved 29 December 2020.
  6. 1 2 Paderno A, Mattavelli D, Rampinelli V, Grammatica A, Raffetti E, Tomasoni M, et al. (December 2020). "Olfactory and Gustatory Outcomes in COVID-19: A Prospective Evaluation in Nonhospitalized Subjects". Otolaryngology–Head and Neck Surgery. 163 (6): 1144–1149. doi:10.1177/0194599820939538. PMC   7331108 . PMID   32600175.
  7. 1 2 Chabot AB, Huntwork MP (September 2021). "Turmeric as a Possible Treatment for COVID-19-Induced Anosmia and Ageusia". Cureus. 13 (9): e17829. doi: 10.7759/cureus.17829 . PMC   8502749 . PMID   34660038.
  8. ↑ Niazkar HR, Zibaee B, Nasimi A, Bahri N (July 2020). "The neurological manifestations of COVID-19: a review article". Neurological Sciences. 41 (7): 1667–1671. doi:10.1007/s10072-020-04486-3. PMC   7262683 . PMID   32483687.
  9. ↑ Jafari E, Azizian R, Asareh A, Akrami S, Karimi N (2022). "Comparative study between bacterial meningitis vs. viral meningitis and COVID-19". Infectious Diseases Research. 3 (2): 9. doi: 10.53388/IDR20220525009 . ISSN   2703-4631.
  10. ↑ "Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)". U.S. Centers for Disease Control and Prevention (CDC). 6 April 2020. Archived from the original on 2 March 2020. Retrieved 19 April 2020.
  11. 1 2 Wang B, Andraweera P, Elliott S, Mohammed H, Lassi Z, Twigger A, et al. (March 2023). "Asymptomatic SARS-CoV-2 Infection by Age: A Global Systematic Review and Meta-analysis". The Pediatric Infectious Disease Journal. 42 (3): 232–239. doi: 10.1097/INF.0000000000003791 . PMC   9935239 . PMID   36730054.
  12. ↑ Multiple sources:
  13. 1 2 Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. (February 2021). "A systematic review of asymptomatic infections with COVID-19". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. 54 (1): 12–16. doi: 10.1016/j.jmii.2020.05.001 . PMC   7227597 . PMID   32425996.
  14. ↑ Oran DP, Topol EJ (September 2020). "Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review". Annals of Internal Medicine. 173 (5): 362–367. doi:10.7326/M20-3012. PMC   7281624 . PMID   32491919.
  15. ↑ Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. (June 2020). "Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths". Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi. 53 (3): 404–412. doi:10.1016/j.jmii.2020.02.012. PMC   7128959 . PMID   32173241.
  16. 1 2 Furukawa NW, Brooks JT, Sobel J (July 2020). "Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic". Emerging Infectious Diseases. 26 (7). doi:10.3201/eid2607.201595. PMC   7323549 . PMID   32364890.
  17. 1 2 Gandhi RT, Lynch JB, Del Rio C (October 2020). "Mild or Moderate Covid-19". The New England Journal of Medicine. 383 (18): 1757–1766. doi: 10.1056/NEJMcp2009249 . PMID   32329974.
  18. ↑ Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. (August 2020). "Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases". BMJ Open. 10 (8): e039856. doi:10.1136/bmjopen-2020-039856. PMC   7409948 . PMID   32759252.
  19. ↑ Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (August 2020). "Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review". JAMA. 324 (8): 782–793. doi: 10.1001/jama.2020.12839 . PMID   32648899. S2CID   220465311.
  20. 1 2 3 4 "Long COVID Basics". US Centers for Disease Control and Prevention. 11 July 2024. Retrieved 27 November 2024.
  21. ↑ CDC (29 March 2022). "Omicron Variant: What You Need to Know". Centers for Disease Control and Prevention. Retrieved 15 June 2022.
  22. 1 2 3 "Coronavirus". World Health Organization (WHO). Retrieved 4 May 2020.
  23. ↑ Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, et al. (September 2020). "Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment". Cell. 182 (6): 1419–1440.e23. doi:10.1016/j.cell.2020.08.001. PMC   7405822 . PMID   32810438.
  24. 1 2 Larsen JR, Martin MR, Martin JD, Kuhn P, Hicks JB (13 August 2020). "Modeling the Onset of Symptoms of COVID-19". Frontiers in Public Health. 8: 473. doi: 10.3389/fpubh.2020.00473 . PMC   7438535 . PMID   32903584. S2CID   221105179.
  25. ↑ Zhao F, Ma Q, Yue Q, Chen H (20 April 2022). "SARS-CoV-2 Infection and Lung Regeneration". Clinical Microbiology Reviews. 35 (2): e00188–21. doi:10.1128/cmr.00188-21. PMC   8809385 . PMID   35107300.
  26. ↑ "Considerations for quarantine of contacts of COVID-19 cases". World Health Organization. WHO recommends that all contacts of individuals with a confirmed or probable COVID-19 be quarantined in a designated facility or at home for 14 days from their last exposure.
  27. ↑ Bikbov B, Bikbov A (2021). "Maximum incubation period for COVID-19 infection: Do we need to rethink the 14-day quarantine policy?". Travel Medicine and Infectious Disease. 40: 101976. doi: 10.1016/j.tmaid.2021.101976 . PMC   7816956 . PMID   33476809. Notably, these incubation periods longer than 14 days were registered not only in sporadic cases, but in a substantial proportion reaching... 5.0% out of 339, 7.7% out of 104... patients with traced contacts
  28. ↑ Grove N (14 June 2021). "Delta variant Covid symptoms 'include headaches, sore throat and runny nose'". The Guardian . London.
  29. ↑ Roberts M (14 June 2021). "Headache and runny nose linked to Delta variant". BBC News . London. Retrieved 2 July 2021.
  30. ↑ Devlin H (15 December 2021). "Londoners with cold symptoms more likely to have Covid, says expert". The Guardian.
  31. ↑ Scribner H (21 December 2021). "Doctor reveals new nightly omicron variant symptom". Deseret News. Archived from the original on 2 January 2022. Retrieved 1 January 2022.
  32. ↑ Quann J (7 July 2022). "Luke O'Neill: Night sweats now a sign of BA.5 COVID variant". Newstalk . Retrieved 10 July 2022.
  33. ↑ "Omicron Symptoms: Here's How They Differ From Other Variants". NBC Chicago.
  34. ↑ Slater J (23 January 2022). "Is a change to your taste or smell a sign of Omicron?". Metro.
  35. ↑ Gul MH, Htun ZM, Inayat A (February 2021). "Role of fever and ambient temperature in COVID-19". Expert Review of Respiratory Medicine. 15 (2): 171–173. doi:10.1080/17476348.2020.1816172. PMC   7544962 . PMID   32901576.
  36. 1 2 Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. (February 2020). "The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China". International Journal of Infectious Diseases. 91: 264–266. doi: 10.1016/j.ijid.2020.01.009 . PMC   7128332 . PMID   31953166.
  37. 1 2 Murthy S, Gomersall CD, Fowler RA (April 2020). "Care for Critically Ill Patients With COVID-19". JAMA. 323 (15): 1499–1500. doi: 10.1001/jama.2020.3633 . PMID   32159735.
  38. 1 2 Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020). "Features, Evaluation and Treatment Coronavirus (COVID-19)". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID   32150360 . Retrieved 18 March 2020.
  39. 1 2 Heymann DL, Shindo N, et al. (WHO Scientific and Technical Advisory Group for Infectious Hazards) (February 2020). "COVID-19: what is next for public health?". Lancet. 395 (10224): 542–545. doi:10.1016/s0140-6736(20)30374-3. PMC   7138015 . PMID   32061313.
  40. ↑ Razaghi A, Szakos A, Al-Shakarji R, Björnstedt M, Szekely L (31 December 2022). "Morphological changes without histological myocarditis in hearts of COVID-19 deceased patients". Scandinavian Cardiovascular Journal. 56 (1): 166–173. doi: 10.1080/14017431.2022.2085320 . ISSN   1401-7431. PMID   35678649. S2CID   249521076.
  41. ↑ Spyropoulos AC, Bonaca MP (January 2022). "Studying the coagulopathy of COVID-19". Lancet. 399 (10320): 118–119. doi:10.1016/S0140-6736(21)01906-1. PMC   8598181 . PMID   34800425.
  42. ↑ Alnima T, Mulder MM, van Bussel BC, Ten Cate H (2022). "COVID-19 Coagulopathy: From Pathogenesis to Treatment". Acta Haematologica. 145 (3): 282–296. doi:10.1159/000522498. PMC   9059042 . PMID   35499460.
  43. ↑ Long B, Brady WJ, Koyfman A, Gottlieb M (July 2020). "Cardiovascular complications in COVID-19". The American Journal of Emergency Medicine. 38 (7): 1504–1507. doi:10.1016/j.ajem.2020.04.048. PMC   7165109 . PMID   32317203.
  44. ↑ Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al. (November 2020). "Association of Cardiac Infection With SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases". JAMA Cardiology. 5 (11): 1281–1285. doi:10.1001/jamacardio.2020.3551. PMC   7385672 . PMID   32730555.
  45. ↑ Basu-Ray I, Almaddah N, Adeboye A, Soos MP (2021). Cardiac Manifestations Of Coronavirus (COVID-19). StatPearls Publishing. PMID   32310612 . Retrieved 5 March 2021.
  46. ↑ Li X, Wang Y, Agostinis P, Rabson A, Melino G, Carafoli E, et al. (July 2020). "Is hydroxychloroquine beneficial for COVID-19 patients?". Cell Death & Disease. 11 (7): 512. doi:10.1038/s41419-020-2721-8. PMC   7341710 . PMID   32641681.
  47. ↑ Zou F, Qian Z, Wang Y, Zhao Y, Bai J (September 2020). "Cardiac Injury and COVID-19: A Systematic Review and Meta-analysis". CJC Open. 2 (5): 386–394. doi:10.1016/j.cjco.2020.06.010. PMC   7308771 . PMID   32838255.
  48. 1 2 3 Rathore SS, Rojas GA, Sondhi M, Pothuru S, Pydi R, Kancherla N, et al. (November 2021). "Myocarditis associated with Covid-19 disease: A systematic review of published case reports and case series". International Journal of Clinical Practice. 75 (11): e14470. doi: 10.1111/ijcp.14470 . PMID   34235815. S2CID   235768792.
  49. ↑ Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. (May 2020). "Myocardial localization of coronavirus in COVID-19 cardiogenic shock". European Journal of Heart Failure. 22 (5): 911–915. doi:10.1002/ejhf.1828. PMC   7262276 . PMID   32275347.
  50. ↑ Kesici S, Aykan HH, Orhan D, Bayrakci B (August 2020). "Fulminant COVID-19-related myocarditis in an infant". European Heart Journal. 41 (31): 3021. doi:10.1093/eurheartj/ehaa515. PMC   7314020 . PMID   32531024.
  51. ↑ Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. (July 2009). "SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS". European Journal of Clinical Investigation. 39 (7): 618–625. doi:10.1111/j.1365-2362.2009.02153.x. PMC   7163766 . PMID   19453650.
  52. ↑ Nicin L, Abplanalp WT, Mellentin H, Kattih B, Tombor L, John D, et al. (May 2020). "Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts". European Heart Journal. 41 (19): 1804–1806. doi:10.1093/eurheartj/ehaa311. PMC   7184464 . PMID   32293672.
  53. ↑ Payus AO, Liew Sat Lin C, Mohd Noh M, Jeffree MS, Ali RA (August 2020). "SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19)". Bosnian Journal of Basic Medical Sciences. 20 (3): 283–292. doi:10.17305/bjbms.2020.4860. PMC   7416180 . PMID   32530389.
  54. 1 2 Rabaan AA, Smajlović S, Tombuloglu H, Ćordić S, Hajdarević A, Kudić N, et al. (6 January 2023). "SARS-CoV-2 infection and multi-organ system damage: A review". Biomolecules and Biomedicine. 23 (1): 37–52. doi:10.17305/bjbms.2022.7762. ISSN   2831-090X. PMC   9901898 . PMID   36124445.
  55. ↑ Even Mild Cases Can Cause "COVID-19 Fog", Columbia University Irving Medical Center, 21 September 2020
  56. ↑ Belluck P (11 October 2020), "How Brain Fog Plagues Covid-19 Survivors", The New York Times
  57. ↑ Carod-Artal FJ (May 2020). "Neurological complications of coronavirus and COVID-19". Revista de Neurología. 70 (9): 311–322. doi:10.33588/rn.7009.2020179. PMID   32329044. S2CID   226200547.
  58. ↑ Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. (June 2020). "Guillain-Barré Syndrome Associated with SARS-CoV-2". The New England Journal of Medicine. 382 (26): 2574–2576. doi:10.1056/NEJMc2009191. PMC   7182017 . PMID   32302082.
  59. 1 2 3 4 5 6 7 Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R (August 2020). "Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis". Mayo Clinic Proceedings. 95 (8): 1621–1631. doi:10.1016/j.mayocp.2020.05.030. PMC   7275152 . PMID   32753137.
  60. 1 2 3 4 5 6 7 8 Marshall M (January 2021). "COVID's toll on smell and taste: what scientists do and don't know". Nature. 589 (7842): 342–343. Bibcode:2021Natur.589..342M. doi: 10.1038/d41586-021-00055-6 . PMID   33452511.
  61. ↑ Gary JB, Gallagher L, Joseph PV, Reed D, Gudis DA, Overdevest JB (January 2023). "Qualitative Olfactory Dysfunction and COVID-19: An Evidence-Based Review with Recommendations for the Clinician". American Journal of Rhinology & Allergy. 37 (1): 95–101. doi:10.1177/19458924221120117. PMC   9379596 . PMID   35957578.
  62. ↑ Zhang R, Sun C, Chen X, Han Y, Zang W, Jiang C, et al. (April 2022). "COVID-19-Related Brain Injury: The Potential Role of Ferroptosis". Journal of Inflammation Research. 15: 2181–2198. doi: 10.2147/JIR.S353467 . PMC   8994634 . PMID   35411172.
  63. 1 2 Marshall M (September 2020). "How COVID-19 can damage the brain". Nature. 585 (7825): 342–343. Bibcode:2020Natur.585..342M. doi:10.1038/d41586-020-02599-5. PMID   32934351. S2CID   221746946.
  64. ↑ Covid linked to 33-fold increase in risk of potentially fatal blood clot Archived 7 April 2022 at the Wayback Machine The Guardian
  65. ↑ Berlin DA, Gulick RM, Martinez FJ (December 2020). Solomon CG (ed.). "Severe Covid-19". The New England Journal of Medicine. 383 (25): 2451–2460. doi: 10.1056/NEJMcp2009575 . PMID   32412710. S2CID   218649520.
  66. ↑ "COVID rash: How the virus attacks the skin". www.colcorona.net. Retrieved 9 December 2022.
  67. ↑ Massey PR, Jones KM (October 2020). "Going viral: A brief history of Chilblain-like skin lesions ("COVID toes") amidst the COVID-19 pandemic". Seminars in Oncology. 47 (5): 330–334. doi:10.1053/j.seminoncol.2020.05.012. PMC   7245293 . PMID   32736881.
  68. ↑ Jabalameli N, Rajabi F, Firooz A, Rezaei N (May 2022). "The Overlap between Genetic Susceptibility to COVID-19 and Skin Diseases". Immunological Investigations. 51 (4): 1087–1094. doi:10.1080/08820139.2021.1876086. PMID   33494631. S2CID   231711934.
  69. ↑ Xu L, Liu J, Lu M, Yang D, Zheng X (May 2020). "Liver injury during highly pathogenic human coronavirus infections". Liver International. 40 (5): 998–1004. doi: 10.1111/liv.14435 . PMC   7228361 . PMID   32170806.
  70. ↑ Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (May 2020). "Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review". JAMA. 323 (18): 1824–1836. doi: 10.1001/jama.2020.6019 . PMID   32282022.
  71. 1 2 Mouffak S, Shubbar Q, Saleh E, El-Awady R (November 2021). "Recent advances in management of COVID-19: A review". Biomedicine & Pharmacotherapy. 143: 112107. doi:10.1016/j.biopha.2021.112107. PMC   8390390 . PMID   34488083.
  72. ↑ Plaçais L, Richier Q, Noël N, Lacombe K, Mariette X, Hermine O (February 2022). "Immune interventions in COVID-19: a matter of time?". Mucosal Immunology. 15 (2): 198–210. doi:10.1038/s41385-021-00464-w. PMC   8552618 . PMID   34711920.
  73. ↑ "Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19". World Health Organization (WHO). 15 May 2020. Retrieved 20 May 2020.
  74. ↑ HAN Archive – 00432 (Report). U.S. Centers for Disease Control and Prevention (CDC). 15 May 2020. Archived from the original on 15 May 2020. Retrieved 20 May 2020.
  75. ↑ Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (February 2020). "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China". Lancet. 395 (10223). Elsevier: 497–506. doi: 10.1016/S0140-6736(20)30183-5 . PMC   7159299 . PMID   31986264.
  76. 1 2 Davis HE, McCorkell L, Vogel JM, Topol EJ (March 2023). "Long COVID: major findings, mechanisms and recommendations". Nature Reviews. Microbiology. 21 (3): 133–146. doi:10.1038/s41579-022-00846-2. PMC   9839201 . PMID   36639608.
  77. ↑ Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. (December 2022). "Pathophysiology and mechanism of long COVID: a comprehensive review". Annals of Medicine. 54 (1): 1473–1487. doi:10.1080/07853890.2022.2076901. PMC   9132392 . PMID   35594336.
  78. 1 2 Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, Solis-Navarro L, Burgos F, Puppo H, et al. (November 2020). "Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis". Pulmonology. 27 (4). Elsevier BV: 328–337. doi:10.1016/j.pulmoe.2020.10.013. PMC   7687368 . PMID   33262076. S2CID   227162748.
  79. ↑ Shaw B, Daskareh M, Gholamrezanezhad A (January 2021). "The lingering manifestations of COVID-19 during and after convalescence: update on long-term pulmonary consequences of coronavirus disease 2019 (COVID-19)". La Radiologia Medica. 126 (1): 40–46. doi:10.1007/s11547-020-01295-8. PMC   7529085 . PMID   33006087.
  80. ↑ Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. (August 2020). "Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery". eClinicalMedicine. 25: 100463. doi:10.1016/j.ijtb.2020.11.003. PMC   7654356 . PMID   32838236.
  81. ↑ "COVID-19 Lung Damage". Johns Hopkins Medicine. 28 February 2022. Retrieved 21 May 2022.
  82. ↑ Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, et al. (August 2022). "Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients". The Lancet Psychiatry. 9 (10): 815–827. doi:10.1016/S2215-0366(22)00260-7. ISSN   2215-0366. PMC   9385200 . PMID   35987197. S2CID   251626731.
  83. 1 2 CDC (1 September 2022). "Post-COVID Conditions". Centers for Disease Control and Prevention. Retrieved 21 September 2022.
  84. 1 2 3 Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. (May 2021). "Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers"". Annals of Clinical and Translational Neurology. 8 (5): 1073–1085. doi:10.1002/acn3.51350. PMC   8108421 . PMID   33755344.
  85. ↑ Landi F, Gremese E, Bernabei R, Fantoni M, Gasbarrini A, Settanni CR, et al. (Gemelli Against COVID-19 Post-Acute Care Study Group) (August 2020). "Post-COVID-19 global health strategies: the need for an interdisciplinary approach". Aging Clinical and Experimental Research. 32 (8): 1613–1620. doi:10.1007/s40520-020-01616-x. PMC   7287410 . PMID   32529595.
  86. ↑ Scordo KA, Richmond MM, Munro N (June 2021). "Post-COVID-19 Syndrome: Theoretical Basis, Identification, and Management". AACN Advanced Critical Care. 32 (2): 188–194. doi:10.4037/aacnacc2021492. PMID   33942071. S2CID   233722062.
  87. ↑ García-Sánchez C, Calabria M, Grunden N, Pons C, Arroyo JA, Gómez-Anson B, et al. (March 2022). "Neuropsychological deficits in patients with cognitive complaints after COVID-19". Brain and Behavior. 12 (3): e2508. doi:10.1002/brb3.2508. PMC   8933779 . PMID   35137561.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.